期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

DPP-4抑制剂超药物说明书用法专家共识 被引量：5

下载PDF
导出
摘要 中国20a以上人口的2型糖尿病的患病率已经达到9．7％。传统降糖药物在2型糖尿病的防治中发挥了重要作用，但仍存在低血糖、体重增加、增加心血管风险以及药物继发失效使血糖控制进行性恶化等局限性：。二肽基肽酶_4（dipeptidylpeptidase-4，DPP-4）抑制剂是近年研发的口服降糖药，因作用机制独特、疗效确定、低血糖发生率少、对体重中性作用或轻度降低、心血管安全性良好等特点受到普遍关注，临床应用越来越广泛。
机构地区 广东省药学会内分泌代谢用药专业委员会
出处 《今日药学》 CAS 2013年第12期777-782,共6页 Pharmacy Today
关键词 抑制剂 药物说明书 2型糖尿病 专家 药物继发失效 心血管安全性 体重增加 心血管风险
分类号 R972.4 [医药卫生—药品]
  • 相关文献

参考文献10

  • 1Zhengpei Zeng,Jin-Kui Yang,Nanwei Tong,Shengli Yan,Xiling Zhang,Yan Gong,Hans-Juergen Woerle.Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial[J].Current Medical Research & Opinion.2013(8)
  • 2Adrian S. DOBS,Barry J. GOLDSTEIN,Pablo ASCHNER,Edward S. HORTON,Guillermo E. UMPIERREZ,Lorraine DURAN,Julie S. HILL,Yu CHEN,Gregory T. GOLM,Ronald B. LANGDON,Debora E. WILLIAMS‐HERMAN,Keith D. KAUFMAN,John M. AMATRUDA,Juan Camilo ARJONA FERREIRA.Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo‐controlled 54‐week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)*[J].Journal of Diabetes.2013(1)
  • 3W. Kothny,J. Foley,P. Kozlovski,Q. Shao,B. Gallwitz,V. Lukashevich.Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus[J].Diabetes Obes Metab.2012(3)
  • 4Andrew J. Lewin,Lisa Arvay,Dacheng Liu,Sanjay Patel,Maximilian von Eynatten,Hans-Juergen Woerle.Efficacy and Tolerability of Linagliptin Added to a Sulfonylurea Regimen in Patients With Inadequately Controlled Type 2 Diabetes Mellitus: An 18-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial[J].Clinical Therapeutics.2012(9)
  • 5Inzucchi, Silvio E,Bergenstal, Richard M,Buse, John B,Diamant, Michaela,Ferrannini, Ele,Nauck, Michael,Peters, Anne L,Tsapas, Apostolos,Wender, Richard,Matthews, David R.Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J].EN.2012(3)
  • 6Ulrike Graefe‐Mody,Peter Rose,Silke Retlich,Arne Ring,Lisa Waldhauser,Rodica Cinca,Hans‐Juergen Woerle.Pharmacokinetics of linagliptin in subjects with hepatic impairment[J].British Journal of Clinical Pharmacology.2012(1)
  • 7S‐I.Harashima,M.Ogura,D.Tanaka,T.Fukushima,Y.Wang,T.Koizumi,M.Aono,Y.Murata,M.Seike,N.Inagaki.Sitagliptin add‐on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes[J].International Journal of Clinical Practice.2012(5)
  • 8Bo Ahrén.GLP-1 for type 2 diabetes[J].Experimental Cell Research.2011(9)
  • 9Jean Doucet,Antonio Chacra,Pierre Maheux,Jane Lu,Susan Harris,Julio Rosenstock.Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus[J].Current Medical Research & Opinion.2011(4)
  • 10S.Del Prato,A. H.Barnett,H.Huisman,D.Neubacher,H.‐J.Woerle,K. A.Dugi.Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial[J].Diabetes Obesity and Metabolism.2011(3)

同被引文献73

  • 1广东省药学会.药品未注册用法专家共识[C],2010年3月18日.
  • 2于沽.儿科学[M].6版.北京:人民卫生出版社.2009:7.
  • 3Heise T, Pieber TR. Towards peakless, reproducible and lon- gaeting insulins=An assessment of the basal analogues based on isoglycasmic clamp studies[J]. Diabetes Obes Metab, 2007,9: 648-659.
  • 4Robertson K J, Schoenle E, Gucev Z, et al. Insulin detemir corn pared with NPH insuhn in children and adolescents with type 1 diabetes[J]. Diabet Med,2007,24:27-34.
  • 5Danne T,Datz N, Endahl L,et al. Imuhn dete deternir is char acterized by a more reproducible pharmacoki-netic profile than insulin glarsine in children and adolescents with type 1 diabets: results from a randomized, double -blind. controlled trial[J]. Pedia- Diabetes, 2008,9: 554-560.
  • 6Vague P,Selam JL,Skeie S,et al. Insulin detemir is associated with more predictable glycemie control and reduced risk of hy- poglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart[J]. Dia- betes Care, 2003,26: 590-596.
  • 7陈丹玲,王淑芳.二甲双胍临床应用新进展[J].国际内科学杂志,2008,35(10):578-581. 被引量：8
  • 8黄红兵,刘韬,陈倩超,林子超,潘莹,黄伟强,刘庆,叶娟平,姚鸣红.3种抗肿瘤靶向治疗药物的临床应用状况调查[J].新医学,2009,40(7):461-464. 被引量：4
  • 9关于印发《药品未注册用法专家共识》的通知[J].今日药学,2010,20(4):1-3. 被引量：143
  • 10苏青.儿童和青少年2型糖尿病的识别和管理[J].中国实用内科杂志,2010,30(9):784-787. 被引量：3

引证文献5

二级引证文献54

今日药学
2013年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部